RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Blueprint Medicines Stock

Blueprint Medicines Net Income 2025

Blueprint Medicines Net Income

-60.94 M USD

Ticker

BPMC

ISIN

US09627Y1091

WKN

A14SDD

In 2025, Blueprint Medicines's profit amounted to -60.94 M USD, a -4.42% increase from the -63.76 M USD profit recorded in the previous year.

The Blueprint Medicines Net Income history

YEARNET INCOME (undefined USD)
2030e1
2029e0.81
2028e0.59
2027e0.3
2026e0.1
2025e-0.06
2024e-0.06
2023-0.51
2022-0.56
2021-0.64
20200.31
2019-0.35
2018-0.24
2017-0.15
2016-0.07
2015-0.06
2014-0.05
2013-0.02

Blueprint Medicines Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Blueprint Medicines, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Blueprint Medicines from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Blueprint Medicines’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Blueprint Medicines. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Blueprint Medicines’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Blueprint Medicines’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Blueprint Medicines’s growth potential.

Blueprint Medicines Revenue, EBIT and net profit per share

DateBlueprint Medicines RevenueBlueprint Medicines EBITBlueprint Medicines Net Income
2030e1.86 B undefined0 undefined1 B undefined
2029e1.61 B undefined641.28 M undefined810.01 M undefined
2028e1.36 B undefined466.58 M undefined594.87 M undefined
2027e1.2 B undefined319.14 M undefined301 M undefined
2026e966.62 M undefined144.92 M undefined102.82 M undefined
2025e726.52 M undefined-45.4 M undefined-60.94 M undefined
2024e519.1 M undefined-207.82 M undefined-63.76 M undefined
2023249.38 M undefined-486.28 M undefined-506.98 M undefined
2022204 M undefined-537.5 M undefined-557.5 M undefined
2021180.1 M undefined-642 M undefined-644.1 M undefined
2020793.7 M undefined308.7 M undefined313.9 M undefined
201966.5 M undefined-361.3 M undefined-347.7 M undefined
201844.5 M undefined-247 M undefined-236.6 M undefined
201721.4 M undefined-151.2 M undefined-148.1 M undefined
201627.8 M undefined-72.6 M undefined-72.5 M undefined
201511.4 M undefined-51.6 M undefined-55.9 M undefined
20140 undefined-39.7 M undefined-46.1 M undefined
20130 undefined-21 M undefined-23.8 M undefined

Blueprint Medicines stock margins

The Blueprint Medicines margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Blueprint Medicines. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Blueprint Medicines.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Blueprint Medicines's sales revenue. A higher gross margin percentage indicates that the Blueprint Medicines retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Blueprint Medicines's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Blueprint Medicines's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Blueprint Medicines's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Blueprint Medicines. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Blueprint Medicines's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Blueprint Medicines Margin History

Blueprint Medicines Gross marginBlueprint Medicines Profit marginBlueprint Medicines EBIT marginBlueprint Medicines Profit margin
2030e96.58 %0 %53.82 %
2029e96.58 %39.81 %50.28 %
2028e96.58 %34.38 %43.84 %
2027e96.58 %26.64 %25.13 %
2026e96.58 %14.99 %10.64 %
2025e96.58 %-6.25 %-8.39 %
2024e96.58 %-40.03 %-12.28 %
202396.58 %-194.99 %-203.3 %
202291.27 %-263.48 %-273.28 %
202190.01 %-356.47 %-357.63 %
202099.95 %38.89 %39.55 %
201996.58 %-543.31 %-522.86 %
201896.58 %-555.06 %-531.69 %
201796.58 %-706.54 %-692.06 %
201696.58 %-261.15 %-260.79 %
201596.58 %-452.63 %-490.35 %
201496.58 %0 %0 %
201396.58 %0 %0 %

Blueprint Medicines Aktienanalyse

What does Blueprint Medicines do?

Blueprint Medicines Corp is a biotechnology company that focuses on the discovery, development, and commercialization of drugs for the treatment of genetic diseases. The company was founded in 2008 by a team of experts in the field of molecular biology, biochemistry, and cancer research and is headquartered in Cambridge, Massachusetts, USA. History Blueprint Medicines started as a spin-off from the Broad Institute of MIT and Harvard, a partnership between the Massachusetts Institute of Technology and Harvard University. The founders' goal was to develop a new type of drugs based on the genetic cause of diseases, rather than just treating symptoms. In 2016, the company went public and has since experienced rapid growth. Blueprint Medicines has generated significant revenue through the sale of its products as well as through licensing agreements with other companies. Business model Blueprint Medicines aims to play a leading role in the development of novel drugs based on the identification and treatment of gene mutations. The company utilizes a combination of computer technology, molecular biology, chemistry, and clinical research to specifically target the causes of diseases. Blueprint Medicines has three main areas of focus: 1. Oncology The main focus of Blueprint Medicines is cancer research. The company has several drugs in development that specifically target mutations associated with certain types of cancer. These drugs aim to improve the effectiveness of cancer treatment and enhance patients' quality of life. 2. Blue Flag Technology Blueprint Medicines has developed a proprietary technology called Blue Flag, which allows the company to rapidly and accurately identify and characterize specific mutations in genes. This technology is key to the development of precision medicine approaches tailored to the specific needs of patients. 3. Rare diseases Blueprint Medicines also has a commitment to developing drugs for the treatment of rare diseases. The company collaborates with patients, physicians, and patient organizations to develop drugs that meet the needs of patients with rare diseases. Products Blueprint Medicines has brought several products to market and is working on developing additional products. Here are some of the key products: 1. Ayvakit Ayvakit is a drug for the treatment of gastrointestinal stromal tumors (GIST) associated with a specific genetic mutation. The drug has proven to be highly effective and has been approved by the U.S. Food and Drug Administration (FDA). 2. Gavreto Gavreto is a drug for the treatment of adult patients with a specific genetic mutation associated with non-small cell lung cancer. The drug is being developed in collaboration with pharmaceutical company Roche. 3. Pralsetinib Pralsetinib is a drug for the treatment of patients with a specific gene mutation associated with thyroid cancer. The drug has proven to be highly effective and has been approved by the U.S. FDA. Conclusion Blueprint Medicines Corp is an emerging biotechnology company that focuses on the discovery, development, and commercialization of drugs for the treatment of genetic diseases. The company has established itself as a leader in the field of personalized medicine and has brought several highly effective products to market. Blueprint Medicines continues to work on developing innovative treatment methods for rare diseases and aims to solidify its position as a leading provider of personalized drugs in the global healthcare market. Blueprint Medicines ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Blueprint Medicines's Profit Margins

The profit margins of Blueprint Medicines represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Blueprint Medicines's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Blueprint Medicines's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Blueprint Medicines's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Blueprint Medicines’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Blueprint Medicines stock

How much profit has Blueprint Medicines made this year?

Blueprint Medicines has made -60.94 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -4.42% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Blueprint Medicines publish its earnings?

Blueprint Medicines publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Blueprint Medicines?

The profits of Blueprint Medicines are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Blueprint Medicines?

You can learn more about the earnings of Blueprint Medicines by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Blueprint Medicines pay?

Over the past 12 months, Blueprint Medicines paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Blueprint Medicines is expected to pay a dividend of 0 USD.

What is the dividend yield of Blueprint Medicines?

The current dividend yield of Blueprint Medicines is .

When does Blueprint Medicines pay dividends?

Blueprint Medicines pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Blueprint Medicines?

Blueprint Medicines paid dividends every year for the past 0 years.

What is the dividend of Blueprint Medicines?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Blueprint Medicines located?

Blueprint Medicines is assigned to the 'Health' sector.

Wann musste ich die Aktien von Blueprint Medicines kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Blueprint Medicines from 1/21/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/21/2025.

When did Blueprint Medicines pay the last dividend?

The last dividend was paid out on 1/21/2025.

What was the dividend of Blueprint Medicines in the year 2024?

In the year 2024, Blueprint Medicines distributed 0 USD as dividends.

In which currency does Blueprint Medicines pay out the dividend?

The dividends of Blueprint Medicines are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Blueprint Medicines stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Blueprint Medicines

Our stock analysis for Blueprint Medicines Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Blueprint Medicines Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.